Miles is Isomorphic Labs' Chief Scientific Officer. He has helped design 25 clinically evaluated drugs and is co-inventor of Kisqali® (Ribociclib), a marketed treatment for breast cancers.

As Chief Scientific Officer at Sosei Heptares, Miles pioneered Structure-Based Drug Design for G Protein-Coupled Receptors (GPCRs). As Director of Chemistry at Astex Pharmaceuticals, he helped establish Fragment-Based Drug Design as a radical new approach to small molecule lead generation. He has also been a team leader at GlaxoSmithKline in medicinal chemistry and chemical technologies. 

He is co-author of over 200 publications and patents and a fellow of the Royal Society of Chemistry. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize for the seminal contributions to GPCR drug discovery made by Sosei Heptares. 

Miles has a degree in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University.